MA55131A - Nouveaux composés hétérocycliques - Google Patents

Nouveaux composés hétérocycliques

Info

Publication number
MA55131A
MA55131A MA055131A MA55131A MA55131A MA 55131 A MA55131 A MA 55131A MA 055131 A MA055131 A MA 055131A MA 55131 A MA55131 A MA 55131A MA 55131 A MA55131 A MA 55131A
Authority
MA
Morocco
Prior art keywords
heterocyclic compounds
new heterocyclic
new
compounds
heterocyclic
Prior art date
Application number
MA055131A
Other languages
English (en)
Other versions
MA55131B1 (fr
Inventor
Uwe Grether
Zbinden Katrin Groebke
Benoit Hornsperger
Carsten Kroll
Bernd Kuhn
Marius Daniel Rinaldo Lutz
Fionn O`Hara
Hans Richter
Didier Rombach
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA55131A publication Critical patent/MA55131A/fr
Publication of MA55131B1 publication Critical patent/MA55131B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
MA55131A 2018-11-22 2019-11-20 Nouveaux composés hétérocycliques MA55131B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18207725 2018-11-22
PCT/EP2019/081870 WO2020104494A1 (fr) 2018-11-22 2019-11-20 Nouveaux composés hétérocycliques

Publications (2)

Publication Number Publication Date
MA55131A true MA55131A (fr) 2022-03-02
MA55131B1 MA55131B1 (fr) 2023-10-31

Family

ID=64453331

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55131A MA55131B1 (fr) 2018-11-22 2019-11-20 Nouveaux composés hétérocycliques

Country Status (30)

Country Link
US (1) US20210387999A1 (fr)
EP (1) EP3883936B1 (fr)
JP (1) JP7444882B2 (fr)
KR (1) KR20210094540A (fr)
CN (1) CN113166170A (fr)
AR (1) AR117139A1 (fr)
AU (1) AU2019383500A1 (fr)
BR (1) BR112021009348A2 (fr)
CA (1) CA3119506A1 (fr)
CL (1) CL2021001330A1 (fr)
CO (1) CO2021007056A2 (fr)
CR (1) CR20210247A (fr)
DK (1) DK3883936T3 (fr)
ES (1) ES2955037T3 (fr)
FI (1) FI3883936T3 (fr)
HR (1) HRP20231083T1 (fr)
HU (1) HUE062913T2 (fr)
IL (1) IL283333B1 (fr)
LT (1) LT3883936T (fr)
MA (1) MA55131B1 (fr)
MX (1) MX2021005714A (fr)
PE (1) PE20211870A1 (fr)
PH (1) PH12021551167A1 (fr)
PL (1) PL3883936T3 (fr)
PT (1) PT3883936T (fr)
RS (1) RS64579B1 (fr)
SG (1) SG11202104206SA (fr)
SI (1) SI3883936T1 (fr)
TW (1) TWI825227B (fr)
WO (1) WO2020104494A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
EP3717477B1 (fr) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG Nouveaux composés hétérocycliques
WO2019134985A1 (fr) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines en tant qu'inhibiteurs de magl
EP3837263A1 (fr) 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
US20210094971A1 (en) * 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
EP4028403B1 (fr) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG Composés de 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one comme inhibiteurs de magl
US20240101552A1 (en) * 2020-09-18 2024-03-28 Shanghai Pharmaceuticals Holding Co., Ltd. Carbonyl heterocyclic compound and application thereof
WO2023130043A1 (fr) * 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiteurs de monoacylglycérol lipase et leur utilisation pour le traitement de l'anxiété
WO2023130050A1 (fr) * 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiteurs de la monoacylglycérol lipase et leur utilisation pour le traitement et la prise en charge de la douleur
AR128333A1 (es) * 2022-01-25 2024-04-17 Hoffmann La Roche Nuevos compuestos heterociclicos
WO2023247670A1 (fr) * 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag Nouveaux composés carbonyles-cycliques hétérocycliques utilisés en tant qu'inhibiteurs de magl
WO2024033277A1 (fr) 2022-08-08 2024-02-15 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques
WO2024033479A1 (fr) * 2022-08-11 2024-02-15 Remynd N.V. Dérivés d'(aza)spiroheptane pour le traitement de troubles neurodégénératifs
WO2024061853A1 (fr) * 2022-09-20 2024-03-28 F. Hoffmann-La Roche Ag Sondes fluorescentes pour magl
WO2024088922A1 (fr) * 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase (magl)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
KR101481872B1 (ko) 2009-09-10 2015-01-12 에프. 호프만-라 로슈 아게 Jak의 억제제
WO2011059118A1 (fr) 2009-11-10 2011-05-19 Kim Hyun Jeen Système de test de perception olfactive
JP5990297B2 (ja) 2015-03-03 2016-09-14 タイヨーエレック株式会社 遊技機
WO2016158956A1 (fr) * 2015-03-30 2016-10-06 武田薬品工業株式会社 Composé hétérocyclique
CN107849015B (zh) 2015-05-21 2021-03-19 葛兰素知识产权发展有限公司 作为pad4抑制剂的苯并咪唑衍生物
BR112018000041A2 (pt) 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same

Also Published As

Publication number Publication date
ES2955037T3 (es) 2023-11-28
RS64579B1 (sr) 2023-10-31
JP7444882B2 (ja) 2024-03-06
CL2021001330A1 (es) 2021-10-29
US20210387999A1 (en) 2021-12-16
AU2019383500A1 (en) 2021-05-27
KR20210094540A (ko) 2021-07-29
AR117139A1 (es) 2021-07-14
MA55131B1 (fr) 2023-10-31
FI3883936T3 (fi) 2023-09-05
EP3883936A1 (fr) 2021-09-29
BR112021009348A2 (pt) 2021-08-10
CO2021007056A2 (es) 2021-06-10
TW202039513A (zh) 2020-11-01
CN113166170A (zh) 2021-07-23
WO2020104494A1 (fr) 2020-05-28
TWI825227B (zh) 2023-12-11
LT3883936T (lt) 2023-09-25
EP3883936B1 (fr) 2023-07-12
PL3883936T3 (pl) 2023-11-20
PE20211870A1 (es) 2021-09-21
PT3883936T (pt) 2023-09-04
PH12021551167A1 (en) 2021-10-25
SI3883936T1 (sl) 2023-10-30
CR20210247A (es) 2021-06-08
HRP20231083T1 (hr) 2023-12-22
IL283333B1 (en) 2024-04-01
SG11202104206SA (en) 2021-06-29
CA3119506A1 (fr) 2020-05-28
DK3883936T3 (da) 2023-09-18
JP2022507919A (ja) 2022-01-18
MX2021005714A (es) 2021-07-21
HUE062913T2 (hu) 2023-12-28
IL283333A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MA55131A (fr) Nouveaux composés hétérocycliques
MA52489A (fr) Nouveaux composés
MA44233A (fr) Nouveaux composés
MA51530A (fr) Composés cycliques fondus
MA50567A (fr) Nouveaux composés de sulfonamide carboxamide
MA49901A (fr) Nouveaux composés de sulfonamide carboxamide
MA49904A (fr) Nouveaux composés de sulfonamide carboxamide
MA56075A (fr) Nouveaux composés de sulfonamide carboxamide
MA53221A (fr) Nouveaux composés de sulfonamide urée
MA52560A (fr) Composés hétéroaryles tétracycliques
MA52948A (fr) Composés
MA44050A (fr) Nouveaux composés
MA49701A (fr) Composés immunomodulateurs
MA51669A (fr) Composés
DK3436444T3 (da) Heterocyklisk forbindelse
MA53003A (fr) Composés
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
MA45221A (fr) Nouveaux composés antibactériens
DK3743337T3 (da) Vilkårlig kasselukker
MA49522A (fr) Nouveaux composés de quinoléinone
UA40089S (uk) Кальян
DK3768669T3 (da) Piperazinazaspiroderivater
DK4018074T3 (da) Borebrøndindretning
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater